Booster Vaccination Reduces Risk of Oxygen Deterioration in COVID-19 Patients

Strategic Insights -

New research published in the Journal of Infection and Chemotherapy has found that booster vaccination significantly reduces the risk of oxygen deterioration in COVID-19 patients, particularly those with comorbidities. The study, conducted by researchers at the Nagoya University Graduate School of Medicine in Japan, analyzed data from 596 hospitalized mild-to-moderate COVID-19 patients during the Omicron wave and found that the booster group showed significantly lower rates of oxygen deterioration and a longer time to deterioration compared to the other groups.

Key Takeaways:

  • The study analyzed data from 596 hospitalized mild-to-moderate COVID-19 patients during the Omicron wave in Japan.
  • The booster group showed significantly lower rates of oxygen deterioration and a longer time to deterioration compared to the other groups.
  • The study found that booster vaccination was significantly associated with a reduced risk of oxygen deterioration after initial treatment, even in elderly patients aged 65 years and older.
  • The booster group had more comorbidities and were older, but still showed better outcomes compared to the other groups.
  • The study demonstrated the effectiveness of booster vaccination on preventing post-treatment oxygen deterioration in hospitalized mild-to-moderate COVID-19 Japanese patients with comorbidities during the Omicron wave.
  • The research concluded that booster vaccination is an effective strategy to prevent post-treatment oxygen deterioration in COVID-19 patients with comorbidities.

Statistics:

  • 596 patients were analyzed in the study, with 141 unvaccinated, 180 primary series, and 275 booster group.
  • The booster group showed a significant reduction in oxygen deterioration rates, with 20.4% of patients experiencing oxygen deterioration compared to 31.5% in the primary series group and 44.7% in the unvaccinated group.
  • The median time to oxygen deterioration was 17.1 days in the booster group, 10.3 days in the primary series group, and 5.5 days in the unvaccinated group.
  • The study found that booster vaccination was associated with a 62% reduction in the risk of oxygen deterioration after initial treatment.

Sources:

  • Effects of Booster Vaccination on Post-Treatment Oxygen Deterioration in Hospitalized Mild-to-Moderate COVID-19 Japanese Patients with comorbidities During the Omicron Wave. Journal of Infection and Chemotherapy, 2025:102764.
  • Journal of Infection and Chemotherapy, published by Elsevier (Radarweg 29, 1043 Nx Amsterdam, Netherlands).
  • Nagoya University Graduate School of Medicine, Aichi, Japan.
  • Shunsaku Hayai, Dept. of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.